Jeff Fairman, VP, Research at Vaxcyte, Inc. (PCVX), sold 9,364 shares at $24.36 ($228K) on 2021-06-28, disclosed to the SEC on 2021-06-30.
Open-market sale of $228k PCVX by VP, Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $24.36 | 4,614 | $112K | 49.3% |
| 2 | $24.36 | 4,614 | $112K | 49.3% |
| 3 | $24.80 | 136 | $3K | 1.5% |
| Total | $24.37 avg | 9,364 | $228K | 100% |
| Filing → |
| PCVX | SELL | 2022-09-07 | $257K | — | Filing → |
| PCVX | SELL | 2022-08-05 | $384K | — | Filing → |
| PCVX | SELL | 2022-05-24 | $105K | — | Filing → |